Cover Image
市場調查報告書

Cleveland BioLabs, Inc.:產品平台分析

Cleveland BioLabs, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 256076
出版日期 內容資訊 英文 30 Pages
訂單完成後即時交付
價格
Back to Top
Cleveland BioLabs, Inc.:產品平台分析 Cleveland BioLabs, Inc. - Product Pipeline Review - 2015
出版日期: 2015年11月18日 內容資訊: 英文 30 Pages
簡介

Cleveland BioLabs, Inc.是開發並商品化癌症及罕見適應症之治療藥與在放射線與化學療法中保護健康組織之藥劑的生物製藥公司。

本報告提供Cleveland BioLabs, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Cleveland BioLabs, Inc.的基本資料

Cleveland BioLabs, Inc.概要

  • 主要資訊
  • 企業資料

Cleveland BioLabs, Inc.:R&D概要

  • 主要的治療範圍

Cleveland BioLabs, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Cleveland BioLabs, Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Cleveland BioLabs, Inc.:藥物簡介

  • entolimod
  • CBLB-612
  • CBLB-613
  • M-606

Cleveland BioLabs, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Cleveland BioLabs, Inc.:最近的開發平台趨勢

Cleveland BioLabs, Inc.:暫停中的計劃

Cleveland BioLabs, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07779CDB

Summary

Global Markets Direct's, 'Cleveland BioLabs, Inc. - Product Pipeline Review - 2015', provides an overview of the Cleveland BioLabs, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cleveland BioLabs, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Cleveland BioLabs, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Cleveland BioLabs, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Cleveland BioLabs, Inc.'s pipeline products

Reasons to buy

  • Evaluate Cleveland BioLabs, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Cleveland BioLabs, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Cleveland BioLabs, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Cleveland BioLabs, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cleveland BioLabs, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Cleveland BioLabs, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Cleveland BioLabs, Inc. Snapshot
    • Cleveland BioLabs, Inc. Overview
    • Key Information
    • Key Facts
  • Cleveland BioLabs, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Cleveland BioLabs, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Cleveland BioLabs, Inc. - Pipeline Products Glance
    • Cleveland BioLabs, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Cleveland BioLabs, Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Cleveland BioLabs, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Cleveland BioLabs, Inc. - Drug Profiles
    • entolimod
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CBLB-612
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CBLB-613
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • M-606
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Cleveland BioLabs, Inc. - Pipeline Analysis
    • Cleveland BioLabs, Inc. - Pipeline Products by Target
    • Cleveland BioLabs, Inc. - Pipeline Products by Route of Administration
    • Cleveland BioLabs, Inc. - Pipeline Products by Molecule Type
    • Cleveland BioLabs, Inc. - Pipeline Products by Mechanism of Action
  • Cleveland BioLabs, Inc. - Recent Pipeline Updates
  • Cleveland BioLabs, Inc. - Dormant Projects
  • Cleveland BioLabs, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Cleveland BioLabs, Inc., Key Information
  • Cleveland BioLabs, Inc., Key Facts
  • Cleveland BioLabs, Inc. - Pipeline by Indication, 2015
  • Cleveland BioLabs, Inc. - Pipeline by Stage of Development, 2015
  • Cleveland BioLabs, Inc. - Monotherapy Products in Pipeline, 2015
  • Cleveland BioLabs, Inc. - Phase III, 2015
  • Cleveland BioLabs, Inc. - Phase I, 2015
  • Cleveland BioLabs, Inc. - Preclinical, 2015
  • Cleveland BioLabs, Inc. - Pipeline by Target, 2015
  • Cleveland BioLabs, Inc. - Pipeline by Route of Administration, 2015
  • Cleveland BioLabs, Inc. - Pipeline by Molecule Type, 2015
  • Cleveland BioLabs, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Cleveland BioLabs, Inc. - Recent Pipeline Updates, 2015
  • Cleveland BioLabs, Inc. - Dormant Developmental Projects,2015

List of Figures

  • Cleveland BioLabs, Inc. - Pipeline by Top 10 Indication, 2015
  • Cleveland BioLabs, Inc. - Pipeline by Stage of Development, 2015
  • Cleveland BioLabs, Inc. - Monotherapy Products in Pipeline, 2015
  • Cleveland BioLabs, Inc. - Pipeline by Top 10 Target, 2015
  • Cleveland BioLabs, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Cleveland BioLabs, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Cleveland BioLabs, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top